Co-development of the CMAP Book: a tool to enhance children's participation in pediatric rehabilitation

Purpose The purpose of the co-development project was to create a tool that enhances children's active participation and agency in rehabilitation and in everyday life. Materials and methods Action research was the methodological approach. Participants in the different phases of the process (2015-2017) were children with disabilities, parents and rehabilitation professionals. The co-development process included: (1) designing the tool's first version, (2) piloting the tool, (3) evaluating the tool by collecting feedback and reflection, (4) generating the tool's final version. Results Through the co-development process, an accommodating and digital tool called the CMAP Book-a description of the child's meaningful activities and participation-was developed. The CMAP Book is used with an electronic app enabling the identification and description of what is meaningful in daily life from the child's perspective with videos, photos, pictures, recording and writing. The tool enables the child, family and professionals to prepare and build collaboration in rehabilitation with flexibility according to child and family needs. Conclusions Use of the CMAP Book promotes the active involvement of the child and parents in designing the rehabilitation process in daily life in partnership with professionals. The stakeholder involvement in the co-development facilitated meaningful results and a concrete tool for rehabilitation.Peer reviewe

Lasten osallistumista ja toimijuutta vahvistavat kuntoutuksen hyvät käytännöt kirjallisuudessa : Kuvaileva kirjallisuuskatsaus

Lasten kuntoutuksen tarkoituksena on turvata ja edistää lapsen toimintakykyä, kehitystä ja osallistumista oman arkensa ikätasoisiin toimiin ja tekemiseen. Lapsen oikeus osallistua pohjaa kansainväliseen YK:n Lapsen oikeuksien sopimukseen. Lapsen osallistuminen ja toimijuus omassa arjessaan on myös merkittävää lapsen hyvinvoinnille. Lapsi- ja perhelähtöisen kuntoutuksen lähtökohtana on lapsen ja perheen tarpeiden tunnistaminen ja aktiivinen osallistuminen. Tämän kuvailevan kirjallisuuskatsauksen tarkoituksena on kartoittaa lapsen osallistumista arjessa arvioivat geneeriset välineet, joiden käytössä lapsi itse on mukana, sekä kuvata menetelmiä ja toimintatapoja, jotka vahvistavat lapsen toimijuutta ja osallistumista kuntoutukseen. Tarkoituksena on myös tunnistaa Lapsen oikeus osallistua kuntoutukseensa – lapsen edun arviointi -hankkeen (Look) tavoitteiden suunnassa potentiaalisia toimintatapoja ja hyviä käytänteitä. Look-hanke on Metropolia AMK:n sekä Lastensuojelun Keskusliiton yhteistyössä toteutuva Kelan rahoittama hanke (2014–2017). Kirjallisuuskatsauksen tuloksina esille tuli 11 sisäänottokriteerit täyttävää lapsen osallistumisen arviointimenetelmää ja 17 lapsen toimijuutta ja osallistumista vahvistavaa menetelmää tai toimintatapaa. Lapsen osallistumisen vahvistaminen kuntoutuksen ammattilaisten ohjaamassa toiminnassa ja lapsen osallistumisen edistäminen omassa arjessa, vaativat suunnitelmallista sekä prosessimaista lapsen toimijuuden vahvistamista. Tämä edellyttää ammattilaisilta osaamista, asennetta ja toiminnan rakenteita, joiden lähtökohtana on lapsen kumppanuus kuntoutuksessaan yhdessä aikuisten kanssa. Look-hankkeen näkökulmasta katsauksessa tunnistettiin kolme potentiaalista toimintatapaa ja yksi lapsen osallistumista arvioiva menetelmä, joiden käyttö vahvistaa lapsen toimijuutta ja osallistumista. Kirjallisuuskatsauksen tuloksia hyödynnettiin yhdessä hankkeen muun aineistonkeruun tulosten kanssa suuntaamaan hankkeen kehittämistoiminnan seuraavia vaiheita

Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied

jiaa099Human papillomavirus (HPV) vaccination of girls with very high (\gt;90\ coverage has the potential to eradicate oncogenic HPVs, but such high coverage is hard to achieve. However, the herd effect (HE) depends both on the HPV type and the vaccination strategy.We randomized 33 Finnish communities into gender-neutral HPV16/18 vaccination, girls-only HPV16/18 vaccination, and hepatitis B virus vaccination arms. In 2007–2010, 11 662 of 20 513 of 40 852 of 39 420 resident boys/girls from 1992 to 1995 birth cohorts consented. In 2010–2014, cervicovaginal samples from vaccinated and unvaccinated girls at age 18.5 years were typed for HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68. Vaccine efficacy for vaccinated girls, HE for unvaccinated girls, and the protective effectiveness (PE) for all girls were estimated. We extended the community-randomized trial results about vaccination strategy with mathematical modeling to assess HPV eradication.The HE and PE estimates in the 1995 birth cohort for HPV18/31/33 were significant in the gender-neutral arm and 150\% and 40\% stronger than in the girls-only arm. Concordantly, HPV18/31/33 eradication was already predicted in adolescents/young adults in 20 years with 75\% coverage of gender-neutral vaccination. With the 75\% coverage, eventual HPV16 eradication was also predicted, but only with the gender-neutral strategy.Gender-neutral vaccination is superior for eradication of oncogenic HPVs.Peer reviewe

Young masculinities, purity and danger: Disparities in framings of boys and girls in policy discourses of sexualisation

One of the reasons why it is ‘hard to explain’ the lack of attention to boys in discourses in sexualisation is that approached head-on, it appears that the focus on girls has no logic and is merely accidental. One might point to the research that is beginning to emerge on the increased visibility of the male body in visual cultures (e.g. Gill, 2009) and to boys’ fashion and embodiment (e.g. Vandenbosch and Eggermont, 2013). However, we propose that the tendency towards a problematisation of girls’ fashion and deportment and the invisibility of boys within policy and media discourses on ‘sexualisation’ is a systemic effect of constructions of gender and sexual subjectivity. In our society, we argue, signifiers of feminine purity operate as a form of symbolic capital, a construction that is not attributed to boys and which is integral scaffolding for the depiction of a subject as threatened by sexualisation. To illustrate our theorising regarding the ‘sexualisation of boys’, we shall examine an apparent exception to the rule: the Papadopoulos Review (2010), which explicitly attends to the sexualisation of boys and ends up re-emphasising rather than analysing the gendered and classed discourses of sexualisation. The Papadopolous Review indicates a moment at which a problematisation of the sexualisation of boys could have been triggered – since attention to both boys and girls was specifically part of the remit of the review – but was not, for specific sociological reasons to do with which subjects are assessed against the criterion of innocence

Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV)

Oncogenic non-vaccine human papillomavirus (HPV) types may conceivably fill the vacated ecological niche of the vaccine types. The likelihood of this may differ by the risk of acquiring HPV infections. We examined occurrence of HPV types among vaccinated and unvaccinated subgroups of 1992–1994 birth cohorts with differing acquisition risks up to 9 years post-implementation of HPV vaccination in 33 Finnish communities randomized to: Arm A (gender-neutral HPV16/18 vaccination), Arm B (girls-only HPV16/18 vaccination and hepatitis B-virus (HBV) vaccination of boys), and Arm C (gender-neutral HBV vaccination). Out of 1992–1994 born resident boys (31,117) and girls (30,139), 8,618 boys and 15,615 girls were vaccinated, respectively, with 20–30% and 50% coverage in 2007–2009. In 2010–2013, 8,868 HPV16/18 and non-HPV vaccinated females, and in 2014–2016, 5,574 originally or later (2010–2013) HPV16/18 vaccinated females attended two cervical sampling visits, aged 18.5 and 22-years. The samples were typed for HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68 using PCR followed by MALDI-TOF MS. HPV prevalence ratios (PR) between Arms A/B vs. C were calculated for Chlamydia trachomatis positives (core-group), and negatives (general population minus core group). At both visits the vaccine-protected HPV type PRs did not significantly differ between the core-group and non-core group. Among the vaccinated 18-year-olds, HPV51 occurrence was overall somewhat increased (PR core = 1.4, PR non-core. = 1.4) whereas the HPV52 occurrence was increased in the core-group only (PR core = 2.5, PR non-core = 0.8). Among the non-HPV vaccinated 18-year-olds, the HPV51/52 PRs were higher in the core-group (PR core = 3.8/1.8, PR non-core = 1.2/1.1). The 22-year-olds yielded no corresponding observations. Monitoring of the sexual risk-taking core-group may detect early tendencies for HPV type replacement

Long‐term follow‐up of human papillomavirus type replacement among young pregnant Finnish females before and after a community‐randomised HPV vaccination trial with moderate coverage

Abstract Large scale human papillomavirus (HPV) vaccination against the most oncogenic high‐risk human papillomavirus (HPV) types 16/18 is rapidly reducing their incidence. However, attempts at assessing if this leads to an increase of nonvaccine targeted HPV types have been hampered by several limitations, such as the inability to differentiate secular trends. We performed a population‐based serological survey of unvaccinated young women over 12 years. The women were under 23‐years‐old, residents from 33 communities which participated in a community‐randomised trial (CRT) with approximately 50% vaccination coverage. Serum samples were retrieved pre‐CRT and post‐CRT implementation. Seropositivity to 17 HPV types was assessed. HPV seroprevalence ratios (PR) comparing the postvaccination to prevaccination era were estimated by trial arm. This was also assessed among the sexual risk‐taking core group, where type replacement may occur more rapidly. In total, 8022 serum samples from the population‐based Finnish Maternity Cohort were retrieved. HPV types 16/18 showed decreased seroprevalence among the unvaccinated in communities only after gender‐neutral vaccination (PR16/18A = 0.8, 95% CI 0.7‐0.9). HPV6/11 and HPV73 were decreased after gender‐neutral vaccination (PR6/11A = 0.8, 95% CI 0.7‐0.9, PR73A = 0.7, 95% CI 0.6‐0.9, respectively) and girls‐only vaccination (PR6/11B = 0.8, 95% CI 0.7‐0.9, PR73B = 0.9, 95% CI 0.8‐1.0). HPV68 alone was increased but only after girls‐only vaccination (PR68B = 1.3, 95% CI 1.0‐1.7, PRcore68B = 2.8, 95% CI 1.2‐6.3). A large‐scale, long‐term follow‐up found no type replacement in the communities with the strongest reduction of vaccine HPV types. Limited evidence for an increase in HPV68 was restricted to girls‐only vaccinated communities and may have been due to secular trends (ClinicalTrials.gov number: NCT00534638)

Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland:a cross-sectional cohort analysis following a cluster randomized trial

Abstract Background: Cervical cancer elimination through human papillomavirus (HPV) vaccination programs requires the attainment of herd effect. Due to its uniquely high basic reproduction number, the vaccination coverage required to achieve herd effect against HPV type 16 exceeds what is attainable in most populations. We have compared how gender-neutral and girls-only vaccination strategies create herd effect against HPV16 under moderate vaccination coverage achieved in a population-based, community-randomized trial. Methods and findings: In 2007–2010, the 1992–1995 birth cohorts of 33 Finnish communities were randomized to receive gender-neutral HPV vaccination (Arm A), girls-only HPV vaccination (Arm B), or no HPV vaccination (Arm C) (11 communities per trial arm). HPV16/18/31/33/35/45 seroprevalence differences between the pre-vaccination era (2005–2010) and post-vaccination era (2011–2016) were compared between all 8,022 unvaccinated women <23 years old and resident in the 33 communities during 2005–2016 (2,657, 2,691, and 2,674 in Arms A, B, and C, respectively). Post- versus pre-vaccination-era HPV seroprevalence ratios (PRs) were compared by arm. Possible outcome misclassification was quantified via probabilistic bias analysis. An HPV16 and HPV18 seroprevalence reduction was observed post-vaccination in the gender-neutral vaccination arm in the entire study population (PR16 = 0.64, 95% CI 0.10–0.85; PR18 = 0.72, 95% CI 0.22–0.96) and for HPV16 also in the herpes simplex virus type 2 seropositive core group (PR16 = 0.64, 95% CI 0.50–0.81). Observed reductions in HPV31/33/35/45 seroprevalence (PR31/33/35/45 = 0.88, 95% CI 0.81–0.97) were replicated in Arm C (PR31/33/35/45 = 0.79, 95% CI 0.69–0.90). Conclusions: In this study we only observed herd effect against HPV16/18 after gender-neutral vaccination with moderate vaccination coverage. With only moderate vaccination coverage, a gender-neutral vaccination strategy can facilitate the control of even HPV16. Our findings may have limited transportability to other vaccination coverage levels